Atara Biotherapeutics, Inc. (ATRA) AI Stock Analysis

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing therapies for patients with solid tumors, hematologic cancers, and autoimmune disorders. Its lead program, Tab-cel (tabelecleucel), is a Phase 3 T-cell immunotherapy targeting Epstein-Barr virus-driven post-transplant lymphoproliferative disease and nasopharyngeal carcinoma. The company is also developing CAR T programs, including ATA2271 and ATA3271 targeting mesothelin, and ATA3219 for B-cell malignancies. Additionally, Atara is evaluating ATA188 in Phase 2 clinical trials for multiple sclerosis. It collaborates with Memorial Sloan Kettering Cancer Center, QIMR Berghofer Medical Research Institute, and H. Lee Moffitt Cancer Center.

Annual revenue rose from $20.3M in FY2021 to $128.9M in FY2024 before decreasing 6.3% to $120.8M in FY2025. In FY2025, gross margin was 82.4%, operating margin reached 29.7%, and net income was $32.7M, or $3.02 per share. However, for the trailing twelve months ended June 30, 2026, revenue was $6.2M, with an operating margin of -627.5% and diluted earnings per share of -$1.30. In the latest quarter ended June 30, 2026, quarterly revenue declined 96.4% year-over-year. For the full year ending December 31, 2026, analysts estimate revenue of $2.8M and an EPS of -$0.95.

As of June 30, 2026, Atara Biotherapeutics held $9.9M in cash and short-term investments and $9.9M in total debt, leaving net debt at $6,000. Total assets stood at $21.0M, and the current ratio was 1.98. Shareholders' equity was negative at -$37.0M. The company has not generated positive annual cash flow from operations, recording operating cash flow of -$50.9M and free cash flow of -$50.9M in FY2025. Over the five-year period through FY2025, its share count expanded by 285.8%.

Atara Biotherapeutics has a market capitalization of $92.1M and an enterprise value of $85.9M. The stock trades at a forward P/E of 16.2x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales ratio is 14.9x versus the peer median of 4.1x, and its EV/EBITDA is 2.2x compared to the peer median of 12.0x. Over the past year, ATRA shares returned -39.8%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock returned -97.6% compared to an 83.0% gain for the index.

Wall Street coverage includes 2 Strong Buy ratings and 1 Hold rating, with no Sell or Strong Sell recommendations. The mean price target of $13.67 represents a 48.9% premium to the October 16, 2026 closing price of $9.18. For the current fiscal year ending December 31, 2026, the consensus EPS estimate is -$0.95 on $2.8M in revenue. For FY2027, 2 analysts project revenue of $40.9M and EPS of $1.54. Atara has beaten EPS estimates in 2 of the last 4 quarters, with its next earnings report scheduled for November 11, 2026.

This page is an AI-written research summary of Atara Biotherapeutics, Inc. (ATRA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ATRA income statement, ATRA balance sheet, ATRA key metrics, ATRA analyst forecast, ATRA chart. See the ATRA stock overview for the latest quote and news.